Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report
Dupilumab, a monoclonal antibody that targets interleukin-4 and interleukin-13, is one of the approved biologic treatments for moderate-to-severe atopic dermatitis. While it is extremely well tolerated with low rates of adverse events, there have been reports of patients with atopic dermatitis manag...
Saved in:
| Main Authors: | Katrina D Cirone, Fiona E Lovegrove |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-02-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X251317811 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Upadacitinib-Associated Ileus Secondary to Psoriasis Induced by Treatment of Atopic Dermatitis with Dupilumab
by: Liu X, et al.
Published: (2024-12-01) -
A case of psoriasis and atopic dermatitis-like rash induced by interleukin-17 and interleukin-23 inhibitors successfully controlled with upadacitinib
by: Toshiki Okazaki, MD, et al.
Published: (2025-09-01) -
Dermatitis herpetiformis successfully treated with dupilumab
by: Sara Al-Khawaga, MD, PhD, et al.
Published: (2025-07-01) -
Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01) -
High Prevalence of Lash Collarettes in Patients with Atopic Dermatitis Treated with Dupilumab
by: Ilaria Trave, et al.
Published: (2025-08-01)